Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16505 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Mengyun Lei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetolo…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Insulin Infusion Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Diabetes mellitus research fund program from Shanghai Medical and Health development foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
This study aims to evaluate the efficacy and safety of a tubeless open‐source hybrid automated insulin delivery (OS‐AID) in managing adults with type 1 diabetes mellitus (T1DM) in China, where commercial AID systems are not accessible.
Methods
In this open‐label randomized crossover study, adults with T1DM aged 18–75 years, glycated haemoglobin (HbA1c) 7%–11% (53‐97 mmol/mol) and who have never used AID previously, were assigned to either Android‐version hybrid OS‐AID (AAPS) or sensor‐augmented insulin pump (SAP) therapy for three months, followed by a crossover to the alternative treatment for an additional three months. The primary endpoint was the percentage of time in range (TIR, 70‐180 mg/dL [3.9–10.0 mmol/L]) during the final two weeks of each treatment phase.
Results
A total of 28 adults with T1DM, with a mean age of 33.6 ± 10.4 years and a T1DM duration of 12.6 ± 7.0 years, were enrolled in this study. The percentage of TIR (70‐180 mg/dL [3.9–10.0 mmol/L]) during the AAPS phase was 75.6 ± 10.3%, significantly higher than the 60.4 ± 15.1% observed during the SAP phase ( p < 0.01). AAPS was notably more effective in managing nocturnal glucose levels compared to diurnal glucose levels (80.9 ± 13.6% vs. 73.8 ± 10.2%, p < 0.01). No significant differences in time below range were observed between the two phases. No severe hypoglycaemia or serious adverse events occurred in either treatment phase.
Conclusion
In this 26‐week trial involving adults with T1DM who had never previously used AID, the tubeless AAPS use at home resulted in a significantly higher percentage of time in the target glucose range without increasing hypoglycaemia risk compared to SAP therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Ping Ling, Yongwen Zhou, Daizhi Yang, Xubin Yang, Jinhua Yan, Wen Xu
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Diabetes mellitus research fund program from Shanghai Medical and Health development foundation
Zitieren
APA
Lei, M., Ling, P., Lin, B., Lv, J., Liu, Z., Zhou, Y., Deng, H., Yang, D., Wang, C., Yang, X., Yan, J., & Xu, W. (2025). Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16505
Vancouver
Lei M, Ling P, Lin B, Lv J, Liu Z, Zhou Y, et al. Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16505
BibTeX
@article{Lei2025,
author = {Lei, Mengyun and Ling, Ping and Lin, Beisi and Lv, Jing and Liu, Zhigu and Zhou, Yongwen and Deng, Hongrong and Yang, Daizhi and Wang, Chaofan and Yang, Xubin and Yan, Jinhua and Xu, Wen},
title = {Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16505}
}
EUVIMED